Andere Sprachen Verrica Pharmaceuticals Inc.

Aktien

A2JPEV

US92511W1080

VRCA

Markt geschlossen - Nasdaq Andere Börsenplätze 19:00:00 03.07.2024			% 5 Tage	% 1. Jan.
7.5 ^USD	+0.40%		+6.38%	+2.46%

15.05.	Verrica Pharmaceuticals ändert Lizenzvereinbarung mit Torii Pharmaceutical für Phase-3-Studie von Ycanth	MT
15.05.	Verrica Pharmaceuticals Inc. kündigt Änderung der Kooperations- und Lizenzvereinbarung mit Torii Pharmaceutical Co. Ltd. zur Finanzierung einer globalen klinischen Phase-3-Studie zur Untersuchung von Ycanth zur Behandlung von gewöhnlichen Warzen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs	01.07.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.	01.07.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30.05.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York	30.05.
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones	30.05.
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15.05.
Verrica Pharmaceuticals : Company Presentation	15.05.
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15.05.
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts	15.05.
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15.05.
Verrica Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q1 Revenue $3.8M, vs. Street Est of $2.7M	13.05.
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results	13.05.
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences	09.05.
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024	08.05.
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA	27.03.
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	26.03.
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA	26.03.
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Verrica Pharmaceuticals Inc.

Aktien

A2JPEV

US92511W1080

VRCA

Andere Sprachen

Filter